open access

Vol 87, No 5 (2016)
Research paper
Published online: 2016-06-02
Get Citation

Alteration of maternal serum irisin levels in gestational diabetes mellitus

Ulku Mete Ural, Serap Baydur Sahin, Yesim Bayoglu Tekin, Medine Cumhur Cüre, Hacer Sezgin
DOI: 10.5603/GP.2016.0013
·
Pubmed: 27304658
·
Ginekol Pol 2016;87(5):395-398.

open access

Vol 87, No 5 (2016)
ORIGINAL PAPERS Obstetrics
Published online: 2016-06-02

Abstract

Objectives: The aim of our study was to compare serum irisin concentrations in pregnant women with and without ges­tational diabetes mellitus (GDM).

Material and methods: This study was performed at the Tertiary Care Center, Department of Obstetrics and Gynecol­ogy, between January 2014 and April 2014. A total of 45 pregnant women with GDM (diabetes group) and 41 BMI- and age-matched healthy pregnant women (control group) were recruited. Maternal serum irisin levels were measured by enzyme-linked immunosorbent assay kit at 24–28 weeks of gestation. An association between maternal serum irisin lev­els and metabolic parameters was analyzed. Body mass index, serum levels of glucose, insulin and irisin were tested and analyzed in the study group and controls.

Results: Pregnant women with GDM had significantly higher fasting plasma glucose (p = 0.001), first-hour OGTT glucose (p = 0.001), second-hour OGTT glucose (p = 0.001), and fasting insulin (p = 0.045) levels as compared to controls. Serum irisin levels were 1.04 ± 0.3 and 1.3 ± 0.2 in pregnant women with GDM and healthy pregnant controls, respectively (p = 0.001). Correlation analysis between irisin levels and anthropometric and biochemical parameters in patients with gestational diabetes revealed that none of the investigated parameters correlated with serum irisin level.

Conclusions: Our results suggest that serum irisin levels might be introduced as a novel marker for GDM, with decreased levels of irisin being indicative of GDM.

Abstract

Objectives: The aim of our study was to compare serum irisin concentrations in pregnant women with and without ges­tational diabetes mellitus (GDM).

Material and methods: This study was performed at the Tertiary Care Center, Department of Obstetrics and Gynecol­ogy, between January 2014 and April 2014. A total of 45 pregnant women with GDM (diabetes group) and 41 BMI- and age-matched healthy pregnant women (control group) were recruited. Maternal serum irisin levels were measured by enzyme-linked immunosorbent assay kit at 24–28 weeks of gestation. An association between maternal serum irisin lev­els and metabolic parameters was analyzed. Body mass index, serum levels of glucose, insulin and irisin were tested and analyzed in the study group and controls.

Results: Pregnant women with GDM had significantly higher fasting plasma glucose (p = 0.001), first-hour OGTT glucose (p = 0.001), second-hour OGTT glucose (p = 0.001), and fasting insulin (p = 0.045) levels as compared to controls. Serum irisin levels were 1.04 ± 0.3 and 1.3 ± 0.2 in pregnant women with GDM and healthy pregnant controls, respectively (p = 0.001). Correlation analysis between irisin levels and anthropometric and biochemical parameters in patients with gestational diabetes revealed that none of the investigated parameters correlated with serum irisin level.

Conclusions: Our results suggest that serum irisin levels might be introduced as a novel marker for GDM, with decreased levels of irisin being indicative of GDM.

Get Citation

Keywords

irisin, pregnant, gestational diabetes mellitus, glucose, insulin

About this article
Title

Alteration of maternal serum irisin levels in gestational diabetes mellitus

Journal

Ginekologia Polska

Issue

Vol 87, No 5 (2016)

Article type

Research paper

Pages

395-398

Published online

2016-06-02

DOI

10.5603/GP.2016.0013

Pubmed

27304658

Bibliographic record

Ginekol Pol 2016;87(5):395-398.

Keywords

irisin
pregnant
gestational diabetes mellitus
glucose
insulin

Authors

Ulku Mete Ural
Serap Baydur Sahin
Yesim Bayoglu Tekin
Medine Cumhur Cüre
Hacer Sezgin

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl